Salubrious effects of dexrazoxane against teniposide-induced DNA damage and programmed cell death in murine marrow cells

Mutagenesis

Volumn 26, Issue 4, 2011, Pages 533-543

  Bakheet, S A ^a   Attia, S M ^a,b   Al Rasheed, N M ^a   Al Harbi, M M ^a   Ashour, A E ^a   Korashy, H M ^a   Abd Allah, A R ^a   Saquib, Q ^c   Al Khedhairy, A A ^c   Musarrat, J ^c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b Cairo University   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLOPHOSPHAMIDE; GLUTATHIONE; RAZOXANE; REACTIVE OXYGEN METABOLITE; TENIPOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CHROMOSOME ABERRATION; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; ENZYME ACTIVITY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; MICRONUCLEUS; MITOSIS RATE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BONE MARROW CELLS; CASPASE 3; CELL CYCLE; CHROMOSOMES, MAMMALIAN; DNA BREAKS; DNA DAMAGE; FLOW CYTOMETRY; GLUTATHIONE; LIPID PEROXIDATION; MALE; MICE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; RAZOXANE; REACTIVE OXYGEN SPECIES; TENIPOSIDE;

MURINAE; MUS;

EID: 79959737364     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/ger013     Document Type: Article

References (70)

1. Wang, J. C. (1996) DNA topoisomerases. Annu. Rev. Biochem., 65, 635-692.
2. Walker, J. V. and Nitiss, J. L. (2002) DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest., 20, 570-589.
3. Giles, G. I. and Sharma, R. P. (2005) Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med. Chem., 1, 383-394.
4. Larsen, A. K., Escargueil, A. E. and Skladanowski, A. (2003) Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther., 99, 167-181.
5. Seiter, K. (2005) Toxicity of the topoisomerase II inhibitors. Expert Opin. Drug Saf., 4, 219-234.
6. Pui, C. H. and Relling, M. V. (2000) Topoisomerase II inhibitor-related acute myeloid leukemia. Br. J. Haematol., 109, 13-23.
7. Ng, A., Taylor, G. M. and Eden, O. B. (2006) Genotoxicity of etoposide: greater susceptibility of MLL than other target genes. Cancer Genet. Cytogenet., 164, 164-167.
8. Attia, S. M. (2008) Mutagenicity of some topoisomerase II-interactive agents. SPJ, 17, 1-24.
9. Kitazawa, J., Ito, E., Arai, K., Yokoyama, M., Fukayama, M. and Imashuku, S. (2001) Secondary acute myelocytic leukemia after successful chemotherapy with etoposide for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Med. Pediatr. Oncol., 37, 153-154.
10. Felix, C. A., Kolaris, C. P. and Osheroff, N. (2006) Topoisomerase II and the etiology of chromosomal translocations. DNA Repair (Amst.), 5, 1093-1108. (Pubitemid 44291622)
11. De Mas, P., Daudin, M., Vincent, M. C., Bourrouillou, G., Calvas, P., Mieusset, R. and Bujan, L. (2001) Increased aneuploidy in spermatozoa from testicular tumour patients after chemotherapy with cisplatin, etoposide and bleomycin. Hum. Reprod., 16, 1204-1208. (Pubitemid 32544692)
12. Gupta, R. S., Bromke, A., Bryant, D. W., Gupta, R., Singh, B. and McCalla, D. R. (1987) Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems. Mutagenesis, 2, 179-186.
13. Jagetia, G. C. and Aruna, R. (1999) Elevation of micronuclei frequency in mouse bone marrow treated with various doses of teniposide (VM-26). Toxicol. Lett., 104, 203-210. (Pubitemid 29078663)
14. Attia, S. M., Schmid, T. E., Badary, O. A., Hamada, F. M. and Adler, I.-D. (2002) Molecular cytogenetic analysis in mouse sperm of chemically induced aneuploidy: studies with topoisomerase II inhibitors. Mutat. Res., 520, 1-13.
15. Attia, S. M. Kliesch, U., Schriever-Schwemmer, G., Badary, O. A., Hamada, F. M. and Adler, I.-D. (2003) Etoposide and merbarone are clastogenic and aneugenic in the mouse bone marrow micronucleus test complemented by fluorescence in situ hybridization with the mouse minor satellite DNA probe. Environ. Mol. Mutagen., 41, 99-103.
16. Wouters, K. A., Kremer, L. C., Miller, T. L., Herman, E. H. and Lipshultz, S. E. (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol., 131, 561-578.
17. Hasinoff, B. B., Yalowich, J. C., Ling, Y. and Buss, J. L. (1996) The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs, 7, 558-567.
18. Pearlman, M., Jendiroba, D., Pagliaro, L., Keyhani, A., Liu, B. and Freireich, E. J. (2003) Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines. Leuk. Res., 27, 617-626.
19. Holm, B., Sehested, M. and Jensen, P. B. (1998) Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin. Cancer Res., 4, 1367-1373.
20. Hofland, K. F., Thougaard, A. V., Dejligbjerg, M., Jensen, L. H., Kristjansen, P. E., Rengtved, P., Sehested, M. and Jensen, P. B. (2005) Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. Clin. Cancer Res., 11, 6722-6829.
21. Hofland, K. F., Thougaard, A. V., Sehested, M. and Jensen, P. B. (2005) Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. Clin. Cancer Res., 11, 3915-3924.
22. Attia, S. M., Al-Anteet, A. A., AL-Rasheed, N. M., Alhaider, A. A. and Al-Harbi, M. M. (2009) Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane. Cancer Chemother. Pharmacol., 64, 837-845.
23. Attia, S. M. (2008) Abatement by naringin of lomefloxacin-induced genomic instability in mice. Mutagenesis, 23, 515-521.
24. Adler, I.-D. (1984) Cytogenetic tests in mammals. In Venitt, S. and Parry, J. M. (eds), Mutagenicity Testing: A Practical Approach. IRI Press, Oxford, pp. 275-306.
25. Tice, R. R., Agurell, E., Anderson, D. et al. (2000) Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen., 35, 206-221.
26. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F. and Riccardi, C. (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139, 271-279.
27. Attia, S. M. (2010) The impact of quercetin on cisplatin-induced clastogenesis and apoptosis in murine marrow cells. Mutagenesis, 25, 281-288.
28. Kunstle, G., Leist, M., Uhlig, S., Revesz, L., Feifel, R., MacKenzie, A. and Wendel, A. (1997) ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha. Immunol. Lett., 55, 5-10.
29. El-Hassan, H., Anwar, K., Macanas-Pirard, P. et al. (2003) Involvement of mitochondria in acetaminophen-induced apoptosis and hepatic injury: roles of cytochrome c, Bax, Bid, and caspases. Toxicol. Appl. Pharmacol., 191, 118-129.
30. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J. (1951) Protein measurement with Folin phenol reagent. J. Biol. Chem., 193, 265-275.
31. Halliwell, B. and Whiteman, M. (2004) Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? Br. J. Pharmacol., 142, 231-255. (Pubitemid 38746160)
32. Ohkawa, H., Ohishi, N. and Yagi, K. (1979) Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 95, 351-358.
33. Ellman, G. L. (1959) Tissue sulfhydryl groups. Arch. Biochem. Biophys., 82, 70-77.
34. Anderson, M. E. (1985) Determination of glutathione and glutathione disulfide in biological samples. In Meister, A. (ed.), Methods Enzymology, 113. Academic Press, NY, USA, pp. 548-555.
35. Patel, S., Pandey, A. K., Bajpayee, M., Parmar, D. and Dhawan, A. (2006) Cypermethrin-induced DNA damage in organs and tissues of the mouse: evidence from the comet assay. Mutat. Res., 607, 176-183.
36. Sieber, S. M., Whang-Peng, J., Botkin, C. and Knutsen, T. (1978) Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16 and VM-26) in mice. Teratology, 18, 31-47. (Pubitemid 8397605)
37. Sasaki, Y. F., Tsuda, S., Izumiyama, F. and Nishidate, E. (1997) Detection of chemically induced DNA lesions in multiple mouse organs (liver, lung, spleen, kidney, and bone marrow) using the alkaline single cell gel electrophoresis (Comet) assay. Mutat. Res., 388, 33-44.
38. Drake, F. H., Hofmann, G. A., Mong, S. M., Bartus, J. O., Hertzberg, R. P., Johnson, R. K., Mattern, M. R. and Mirabelli, C. K. (1989) In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res., 49, 2578-2583.
39. Chen, M. and Beck, W. T. (1995) Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26. Cancer Res., 55, 1509-1516.
40. Sehested, M., Jensen, P. B., Sørensen, B. S., Holm, B., Friche, E. and Demant, E. J. (1993) Antagonistic effect of the cardioprotector (+)-1,2- bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem. Pharmacol., 46, 389-393.
41. Li, J., Chen, W., Zhang, P. and Li, N. (2006) Topoisomerase II trapping agent teniposide induces apoptosis and G2/M or S phase arrest of oral squamous cell carcinoma. World J. Surg. Oncol., 4, 41.
42. Micić, M., Bihari, N., Jaksić, Z., Müller, W. E. and Batel, R. (2002) DNA damage and apoptosis in the mussel Mytilus galloprovincialis. Mar. Environ. Res., 53, 243-262.
43. Holm, B., Jensen, P. B., Sehested, M. and Hansen, H. H. (1994) In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin. Cancer Chemother. Pharmacol., 34, 503-508.
44. Hasinoff, B. B., Schroeder, P. E. and Patel, D. (2003) The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol. Pharmacol., 64, 670-678.
45. Sawyer, D. B., Fukazawa, R., Arstall, M. A. and Kelly, R. A. (1999) Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ. Res., 84, 257-265.
46. Popelová, O., Sterba, M., Hasková, P. et al. (2009) Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br. J. Cancer, 101, 792-802.
47. Hasinoff, B. B., Kuschak, T. I., Yalowich, J. C. and Creighton, A. M. (1995) A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem. Pharmacol., 50, 953-958.
48. Haim, N., Roman, J., Nemec, J. and Sinha, B. K. (1986) Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem. Biophys. Res. Commun., 135, 215-220.
49. Clark, P. I. and Slevin, M. L. (1987) The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet., 12, 223-252.
50. Sinha, B. K., Eliot, H. M. and Kalayanaraman, B. (1988) Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug VP-16. FEBS Lett., 227, 240-244. (Pubitemid 18033882)
51. Kalyanaraman, B., Nemec, J. and Sinha, B. K. (1989) Characterization of free radicals produced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives: an ESR Study. Biochemistry, 28, 4839-4846.
52. Ladner, C., Ehninger, G., Gey, K. F. and Clemens, M. R. (1989) Effect of etoposide (VP16-213) on lipid peroxidation and antioxidant status in a high-dose radiochemotherapy regimen. Cancer Chemother. Pharmacol., 25, 210-212.
53. Limoli, C. L., Hartmann, A., Shephard, L., Yang, C. R., Boothman, D. A., Bartholomew, J. and Morgan, W. F. (1998) Apoptosis, reproductive failure, and oxidative stress in Chinese hamster ovary cells with compromised genomic integrity. Cancer Res., 58, 3712-3718.
54. Long, B. H. (1992) Mechanisms of action of teniposide (VM-26) and comparison with etoposide (VP-16). Semin. Oncol., 19, 3-19.
55. Mans, D. R., Lafleur, M. V., Westmijze, E. J., Horn, I. R., Bets, D., Schuurhuis, G. J., Lankelma, J. and Retèl, J. (1992) Reactions of glutathione with the catechol, the ortho-quinone and the semiquinone free radical of etoposide. Consequences for DNA inactivation. Biochem. Pharmacol., 43, 1761-1768.
56. Ritov, V. B., Goldman, R., Stoyanovsky, D. A., Menshikova, E. V. and Kagan, V. E. (1995) Antioxidant paradoxes of phenolic compounds: peroxyl radical scavenger and lipid antioxidant, etoposide (VP-16), inhibits sarcoplasmic reticulum Ca(2+)-ATPase via thiol oxidation by its phenoxyl radical. Arch. Biochem. Biophys., 321, 140-152.
57. Acharya, A., Das, I., Chandhok, D. and Saha, T. (2010) Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid. Med. Cell. Longev., 3, 23-34.
58. Attia, S. M. (2010) Deleterious effects of reactive metabolites. Oxid. Med. Cell. Longev., 3, 238-253.
59. Lebrecht, D., Geist, A., Ketelsen, U. P., Haberstroh, J., Setzer, B. and Walker, U. A. (2007) Dexrazoxane prevents doxorubicin-induced longterm cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br. J. Pharmacol., 151, 771-778.
60. Hasinoff, B. B. and Herman, E. H. (2007) Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc. Toxicol., 7, 140-144.
61. Junjing, Z., Yan, Z. and Baolu, Z. (2010) Scavenging effects of dexrazoxane on free radicals. J. Clin. Biochem. Nutr., 47, 238-245.
62. Galetta, F., Franzoni, F., Cervetti, G. et al. (2010) In vitro and in vivo study on the antioxidant activity of dexrazoxane. Biomed. Pharmacother., 64, 259-263.
63. Hochster, H., Liebes, L., Wadler, S., Oratz, R., Wernz, J. C., Meyers, M., Green, M., Blum, R. H. and Speyer, J. L. (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J. Natl Cancer Inst., 84, 1725-1730.
64. Jakobsen, P., Sorensen, B., Bastholt, L., Mirza, M. R., Gjedde, S. B., Mouridsen, H. T. and Rose, C. (1994) The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast cancer patients. Cancer Chemother. Pharmacol., 35, 45-52.
65. Schroeder, P. E., Jensen, P. B., Sehested, M., Hofland, K. F., Langer, S. W. and Hasinoff, B. B. (2003) Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemother. Pharmacol., 52, 167-174.
66. Schroeder, P. E., Hofland, K. F., Jensen, P. B., Sehested, M., Langer, S. W. and Hasinoff, B. B. (2004) Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemother. Pharmacol., 53, 91-93.
67. Pearlman, M., Jendiroba, D., Pagliaro, L., Keyhani, A., Liu, B., Freireich, E. J. and Travis, E. (2003) Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicity. Cancer Chemother. Pharmacol., 52, 477-481.
68. Langer, S. W., Sehested, M. and Jensen, P. B. (2001) Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann. Oncol., 12, 405-410.
69. Swain, S. M. and Vici, P. (2004) The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J. Cancer Res. Clin. Oncol., 130, 1-7.
70. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. and Gianni, L. (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 56, 185-229.